×
S&P 500   3,778.24 (-0.19%)
DOW   30,709.13 (-0.22%)
QQQ   279.05 (-0.44%)
AAPL   136.98 (+0.19%)
MSFT   256.45 (-0.15%)
META   157.00 (-2.64%)
GOOGL   2,150.50 (-1.32%)
AMZN   107.97 (+1.66%)
TSLA   674.05 (+0.09%)
NVDA   146.19 (-3.56%)
NIO   21.09 (-2.90%)
BABA   115.09 (+1.24%)
AMD   73.67 (-3.66%)
MU   52.49 (-5.05%)
CGC   2.86 (+0.35%)
T   21.03 (+0.33%)
GE   62.99 (-1.07%)
F   11.21 (+0.72%)
DIS   95.06 (+0.70%)
AMC   13.52 (-0.22%)
PFE   51.75 (-1.30%)
PYPL   70.20 (+0.52%)
NFLX   176.40 (+0.87%)
S&P 500   3,778.24 (-0.19%)
DOW   30,709.13 (-0.22%)
QQQ   279.05 (-0.44%)
AAPL   136.98 (+0.19%)
MSFT   256.45 (-0.15%)
META   157.00 (-2.64%)
GOOGL   2,150.50 (-1.32%)
AMZN   107.97 (+1.66%)
TSLA   674.05 (+0.09%)
NVDA   146.19 (-3.56%)
NIO   21.09 (-2.90%)
BABA   115.09 (+1.24%)
AMD   73.67 (-3.66%)
MU   52.49 (-5.05%)
CGC   2.86 (+0.35%)
T   21.03 (+0.33%)
GE   62.99 (-1.07%)
F   11.21 (+0.72%)
DIS   95.06 (+0.70%)
AMC   13.52 (-0.22%)
PFE   51.75 (-1.30%)
PYPL   70.20 (+0.52%)
NFLX   176.40 (+0.87%)
S&P 500   3,778.24 (-0.19%)
DOW   30,709.13 (-0.22%)
QQQ   279.05 (-0.44%)
AAPL   136.98 (+0.19%)
MSFT   256.45 (-0.15%)
META   157.00 (-2.64%)
GOOGL   2,150.50 (-1.32%)
AMZN   107.97 (+1.66%)
TSLA   674.05 (+0.09%)
NVDA   146.19 (-3.56%)
NIO   21.09 (-2.90%)
BABA   115.09 (+1.24%)
AMD   73.67 (-3.66%)
MU   52.49 (-5.05%)
CGC   2.86 (+0.35%)
T   21.03 (+0.33%)
GE   62.99 (-1.07%)
F   11.21 (+0.72%)
DIS   95.06 (+0.70%)
AMC   13.52 (-0.22%)
PFE   51.75 (-1.30%)
PYPL   70.20 (+0.52%)
NFLX   176.40 (+0.87%)
S&P 500   3,778.24 (-0.19%)
DOW   30,709.13 (-0.22%)
QQQ   279.05 (-0.44%)
AAPL   136.98 (+0.19%)
MSFT   256.45 (-0.15%)
META   157.00 (-2.64%)
GOOGL   2,150.50 (-1.32%)
AMZN   107.97 (+1.66%)
TSLA   674.05 (+0.09%)
NVDA   146.19 (-3.56%)
NIO   21.09 (-2.90%)
BABA   115.09 (+1.24%)
AMD   73.67 (-3.66%)
MU   52.49 (-5.05%)
CGC   2.86 (+0.35%)
T   21.03 (+0.33%)
GE   62.99 (-1.07%)
F   11.21 (+0.72%)
DIS   95.06 (+0.70%)
AMC   13.52 (-0.22%)
PFE   51.75 (-1.30%)
PYPL   70.20 (+0.52%)
NFLX   176.40 (+0.87%)
NASDAQ:UTHR

United Therapeutics Stock Forecast, Price & News

$235.38
-0.26 (-0.11%)
(As of 07/1/2022 12:19 PM ET)
Add
Compare
Today's Range
$232.87
$236.33
50-Day Range
$174.81
$241.14
52-Week Range
$158.38
$243.30
Volume
2,929 shs
Average Volume
479,542 shs
Market Capitalization
$10.66 billion
P/E Ratio
16.29
Dividend Yield
N/A
Price Target
$244.50
30 days | 90 days | 365 days | Advanced Chart

Receive UTHR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

UTHR Stock Forecast (MarketRank)

Overall MarketRank

2.25 out of 5 stars

Medical Sector

340th out of 1,429 stocks

Pharmaceutical Preparations Industry

141st out of 682 stocks

Analyst Opinion: 1.4Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 2.5 5 -4 -3 -2 -1 -
United Therapeutics logo

About United Therapeutics (NASDAQ:UTHR)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

UTHR Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:UTHR
CUSIP
91307C10
Employees
965
Year Founded
1996

Company Calendar

Last Earnings
5/04/2022
Today
7/01/2022
Next Earnings (Estimated)
8/03/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$244.50
High Stock Price Forecast
$300.00
Low Stock Price Forecast
$203.00
Forecasted Upside/Downside
+3.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.85714285714286
Research Coverage
7 Analysts

Profitability

Net Income
$475.80 million
Pretax Margin
49.21%

Debt

Sales & Book Value

Annual Sales
$1.69 billion
Cash Flow
$11.50 per share
Book Value
$87.90 per share

Miscellaneous

Free Float
39,819,000
Market Cap
$10.66 billion
Optionable
Optionable
Beta
0.62

Social Links















United Therapeutics Frequently Asked Questions

Should I buy or sell United Therapeutics stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" United Therapeutics stock.
View analyst ratings for United Therapeutics
or view top-rated stocks.

What is United Therapeutics' stock price forecast for 2022?

7 Wall Street research analysts have issued 1 year price targets for United Therapeutics' shares. Their UTHR stock forecasts range from $203.00 to $300.00. On average, they predict United Therapeutics' share price to reach $244.50 in the next twelve months. This suggests a possible upside of 4.2% from the stock's current price.
View analysts' price targets for United Therapeutics
or view top-rated stocks among Wall Street analysts.

How has United Therapeutics' stock performed in 2022?

United Therapeutics' stock was trading at $216.08 at the beginning of the year. Since then, UTHR stock has increased by 8.6% and is now trading at $234.64.
View the best growth stocks for 2022 here
.

When is United Therapeutics' next earnings date?

United Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for United Therapeutics
.

How were United Therapeutics' earnings last quarter?

United Therapeutics Co. (NASDAQ:UTHR) posted its quarterly earnings results on Wednesday, May, 4th. The biotechnology company reported $5.03 EPS for the quarter, topping the consensus estimate of $2.96 by $2.07. The biotechnology company had revenue of $461.90 million for the quarter, compared to analyst estimates of $420.02 million. United Therapeutics had a net margin of 38.87% and a trailing twelve-month return on equity of 17.62%. The firm's revenue for the quarter was up 21.8% on a year-over-year basis. During the same period in the prior year, the firm earned $0.61 EPS.
View United Therapeutics' earnings history
.

Who are United Therapeutics' key executives?

United Therapeutics' management team includes the following people:
  • Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D., Founder, Chairman & CEO (Age 67, Pay $3.51M)
  • Mr. Michael I. Benkowitz, Pres & COO (Age 50, Pay $1.96M)
  • Mr. James C. Edgemond, CFO & Treasurer (Age 54, Pay $1.42M)
  • Mr. Paul A. Mahon J.D., Exec. VP, Gen. Counsel & Corp. Sec. (Age 58, Pay $1.67M)
  • Mr. Dewey Steadman C.F.A., Head of Investor Relations
  • Ms. Holly Hobson, Associate VP of HR
  • Kevin T. Gray, Sr. VP of Strategic Operations & Logistics
  • Mr. Patrick Poisson, Exec. VP of Technical Operations (Age 54)
  • Mr. Gil Golden, Sr. VP & Chief Medical Officer
  • Dr. Leigh Peterson, VP of Product Devel.

What is Martine A. Rothblatt's approval rating as United Therapeutics' CEO?

64 employees have rated United Therapeutics CEO Martine A. Rothblatt on Glassdoor.com. Martine A. Rothblatt has an approval rating of 88% among United Therapeutics' employees.

What other stocks do shareholders of United Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), (CELG), General Electric (GE), Johnson & Johnson (JNJ), Skyworks Solutions (SWKS), Allergan (AGN) and Pfizer (PFE).

What is United Therapeutics' stock symbol?

United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR."

How do I buy shares of United Therapeutics?

Shares of UTHR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is United Therapeutics' stock price today?

One share of UTHR stock can currently be purchased for approximately $234.64.

How much money does United Therapeutics make?

United Therapeutics (NASDAQ:UTHR) has a market capitalization of $10.63 billion and generates $1.69 billion in revenue each year. The biotechnology company earns $475.80 million in net income (profit) each year or $14.45 on an earnings per share basis.

How many employees does United Therapeutics have?

United Therapeutics employs 965 workers across the globe.

When was United Therapeutics founded?

United Therapeutics was founded in 1996.

How can I contact United Therapeutics?

United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The official website for United Therapeutics is www.unither.com. The biotechnology company can be reached via phone at (301) 608-9292, via email at [email protected], or via fax at 301-608-9291.

This page (NASDAQ:UTHR) was last updated on 7/1/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.